Furthermore, in breast cancer patients with ER-positive primary tumors who received tamoxifen treatment, FOXC1 expression is associated with decreased or undetectable ER expression in recurrent tumors post endocrine treatment. This evidence concerns the gene FOXC1 and breast carcinoma.